COOPERSTONE BRENDA 4

What Happened Brenda Cooperstone, a director of Lexeo Therapeutics (LXEO), received a grant of 35,000 derivative shares (an option award) on June 25, 2026. The award was reported at $0.00 per share (no cash purchase). This is a compensation/award transaction rather than an open-market buy or sale.

Key Details

• Transaction date and type: 2026-06-25 — Grant/award (derivative instrument).
• Amount: 35,000 shares; reported price $0.00 (derivative award).
• Vesting note (from filing): 100% of the shares underlying the option vest and become exercisable on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: Form 4 filed 2026-06-29 (4 days after the grant); this appears to be later than the usual 2-business-day Form 4 deadline.

Context This filing documents an option/award grant, which does not represent an immediate market purchase or sale. Such awards are commonly part of director compensation and typically vest over time; they do not necessarily indicate current buying/selling sentiment. If and when options are exercised or shares are sold, separate Form 4s would report those transactions.